Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?

Table 3 Univariate analysis of adjusted PSA values and volume-adjusted PSA parameters in patients with gray zone PSA levels

	Pathologic report of prostate biopsy		Odds ratio	95% CI	P value
	Non-Prostate Ca. (n = 152)	Prostate Ca. (n = 152)	Odds ratio	95% CI	P value
PSA			1.731	1.030–2.907	0.038
< 8.0 ng/mL	120 (78.9%)	104 (68.4%)
≥ 8.0 ng/mL	32 (21.1%)	48 (31.6%)
Adjusted PSA
RETzPSA			3.563	2.168–5.855	< 0.001
< 3.8 ng/mL	77 (50.7%)	34 (22.4%)
≥ 3.8 ng/mL	75 (49.3%)	118 (77.6%)
EPHPSA			2.365	1.490–3.752	< 0.001
< 1.0 ng/mL	98 (64.5%)	66 (43.4%)
≥ 1.0 ng/mL	54 (35.5%)	86 (56.6%)
Volume-adjusted PSA parameters
PSAD			5.171	3.171–8.432	< 0.001
< 0.18 ng/mL/cc	109 (71.7%)	50 (32.9%)
≥ 0.18 ng/mL/cc	43 (28.3%)	102 (67.1%)
conventional PSAD			3.432	2.095–5.623	< 0.001
< 0.15 ng/mL/cc	77 (50.7%)	35 (23.0%)
≥ 0.15 ng/mL/cc	75 (49.3%)	117 (77.0%)
ETzD			4.054	2.513–6.540	< 0.001
< 0.04 ng/mL/cc	98 (64.5%)	47 (30.9%)
≥ 0.04 ng/mL/cc	54 (35.5%)	105 (69.1%)
PZPSAD			2.370	1.492–3.763	< 0.001
< 0.3 ng/mL/cc	99 (65.1%)	67 (44.1%)
≥ 0.3 ng/mL/cc	53 (34.9%)	85 (55.9%)

PSA prostate-specific antigen, RETzPSA relative extra transitional zone PSA, EPHPSA estimated post holmium laser enucleation of the prostate PSA, PSAD PSA density, PSAD1 using cut-off value by ROC curve analysis, PSAD2 using conventional cut-off value (0.15 ng/mL³), ETzD extra transitional zone PSA density, PZPSAD peripheral zone PSA density

ISSN: 1471-2407